(NASDAQ:PESI), ATLANTA, Nov. 10, 2025 (GLOBE NEWSWIRE) — Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced financial results for the third quarter ended September 30, 2025, and provided a business update. Mark Duff, President and Chief Executive Officer (CEO) of the Company, commented, “We are pleased to report improved performance driven by a […]

(TSX-V:ZAC),(Pinksheets:ZCTSF),(PinkSheets:ZCTSF),(Boerse Frankfurt – Freiverkehr:7TV),(Boerse Frankfurt – Freiverkehr:7TV.F),(TSX:MDI), VANCOUVER, British Columbia, Nov. 10, 2025 (GLOBE NEWSWIRE) — Zacatecas Silver Corp. (TSXV: ZAC; OTC: ZCTSF; FSE: 7TV) is pleased to announce that it has entered into a new community access agreement with the Ejido Panuco at its flagship Zacatecas Silver Project in Zacatecas, Mexico. The Company has

Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results GlobeNewswire November 10, 2025 SEP-479 Selected as Next-Generation Oral PTH1R Agonist Development Candidate SEP-631 (MRGPRX2 NAM) Phase 1 Clinical Trial in Healthy Volunteers Ongoing Robust Financial Position of $561.6 Million Expected to Support Operations at Least into 2029 SOUTH SAN FRANCISCO, Calif., Nov. 10,

BELLEVUE, Wash., Nov. 10, 2025 (GLOBE NEWSWIRE) — Atana, the leading behavior-based learning and development solutions provider, today announced the general availability of Atana Organizational Insights. This powerful analytics solution visualizes what's truly happening in an organization through data gathered naturally with Atana courses, in the flow of learning. The data-driven insights are supported by

Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody GlobeNewswire November 10, 2025 Interim Phase 1 results for APG333 exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers for 6 months following a single dose, supporting potential 3- and

(NASDAQ:EDIT), In vivo preclinical proof-of-concept data presented at AHA and ESGCT demonstrating >90% LDL-C reduction in non-human primates supports EDIT-401's potential as a best-in-class, one-time therapy Company on track to submit IND/CTA for EDIT-401 by mid-2026 and achieve initial human proof-of-concept data by year-end 2026 Extended cash runway into the third quarter of 2027, enabling

Perma-Fix Reports Financial Results and Provides Business Update for the Third Quarter of 2025 GlobeNewswire November 10, 2025 ATLANTA, Nov. 10, 2025 (GLOBE NEWSWIRE) — Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced financial results for the third quarter ended September 30, 2025, and provided a business update. Mark Duff, President and Chief

(TSX-V:ELBM),(NASDAQ:ELBM), TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) — Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) (“Electra” or the “Company“), a leader in advancing North America's critical minerals processing, announces the issuance of a major mechanical, piping, electrical and instrumentation (“SMPEI”) tender package as part of its refinery construction works in Temiskaming Shores, Ontario. The

Zacatecas Silver Secures Community Access Agreement at Panuco and Signs Drill Contract with Major Drilling GlobeNewswire November 10, 2025 VANCOUVER, British Columbia, Nov. 10, 2025 (GLOBE NEWSWIRE) — Zacatecas Silver Corp. (TSXV: ZAC; OTC: ZCTSF; FSE: 7TV) is pleased to announce that it has entered into a new community access agreement with the Ejido Panuco

(NasdaqGM:RYTM), – Phase 3 TRANSCEND trial data showed setmelanotide achieved significant BMI reductions in patients with acquired hypothalamic obesity on concomitant treatment with GLP-1 therapy – – Analysis of data from Phase 3 TRANSCEND trial show clinically meaningful changes in cardiometabolic parameters in patients with acquired hypothalamic obesity treated with setmelanotide for 52 weeks –